L.KH. MUKHAMATGALEEVA¹², Z.A. AFANASIEVA²

¹Republican Oncologic Dispensary of the Republic of Mariy El, 22a Osipenko St., Ioshkar-Ola,Russian Federation 424000

²Kazan State Medical Academy, 36 Butlerova St., Kazan, Russian Federation 420012

Mukhamatgaleeva L.Kh.—Head of Department of Outpatient Diagnostics and Treatment, postgraduate student of the Department of Oncology and Surgery, tel. +7-961-336-12-35, e-mail: luizamed@ya.ru¹^,²

Afanasieva Z.A. —D. Med. Sc., Professor of the Department of Oncology and Surgery, tel. +7-917-886-29-23, e-mail: z-afanasieva@mail.ru²

Skin melanoma is a metabolically active heterogeneous tumor. Melanoblasts can produce classical stress neurotransmitters, neuropeptides and other biologically active substances. Experimental studies show that neurotransmitters are the potent vascularization stimulators, and stimulate neoangiogenesis and metastasis through the production of pro-angiogenic factors. Neurotransmitters of sympathoadrenal system are potent modulators of tumor growth; their definition opens up new possibilities for diagnosis of the primary tumor, metastasis and recurrence of melanoma.

Key words: melanoma, diagnosis, skin neuroendocrine system, neurotransmitters, neoangiogenesis.

 

 

REFERENCES

1. Lemekhov V.G. Epidemiology, risk factors, screening melanoma. Prakticheskaya onkologiya, 2001, no. 4, pp. 3-6 (in Russ.).

2. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N. Engl. J. Med., 2004, vol. 351, pp. 998-1012.

3. Lum S.S., Fletcher W.S., O’Dorisio M.S. et al. Distribution and functional significance of somatostatin receptors in malignant melanoma. World J. Surg., 2001, vol. 25, no. 4, pp. 407-12.

4. Miller A.J., Mihm M.C. Melanoma. N Engl J Med., 2006, vol. 355, pp. 51-65.

5. Markovic S.N., Erickson L.A., Rao R.D. et al. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clin. Proc., 2007, vol. 82, no. 3, pp. 364-380.

6. Vagner R.I., Anisimov V.V., Barchuk A.S. Melanoma kozhi [Melanoma skin]. Saint Petersburg: Nauka, 1996. Part. 2. 350 p.

7. Demidov L.V. Melanoma skin. Mikrostadirovanie clinical and histological classification. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney, 1998, no. 4, pp. 12-17 (in Russ.).

8. Zelger B.G., Steiner H., Wambacher B., Zelger B. Malignant melanomas simulating various types of soft tissue tumors. Dermatol. Surg., 1997, vol. 23, no. 11, pp. 1047-54.

9. Banerjee S.S., Eyden B. Divergent differentiation in malignant melanomas: a review. Histopathology, 2008, vol. 52, no. 2, pp. 119-129.

10. Lutgendorf S.K., Cole S., Costanzo E. et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res., 2003, vol. 9, pp. 4514-4521.

11. Eyden B., Pandit D., Banerjee S.S. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology, 2005, vol. 47, no. 4, pp. 402-409.

12. Slominski A., Wortsman J., Tuckey R.C., Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol., 2007, vol. 266, pp. 143-149.

13. Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol., 2009, vol. 18, no. 9, pp. 760-763.

14. Slominski A., Wortsman J. Neuroendocrinology of the skin. Endocrine Rev., 2000, vol. 21, pp. 457-487.

15. Abramov V.V., Egorov D.N., Vardosanidze V.K., Kozlov V.V. Nervnaya i immunnaya sistema v kantserogeneze [Nervous and immune systems in carcinogenesis]. Novosibirsk: SO RAMN, 1998. 102 p.

16. Bershteyn L.M. Gormonal’nyy kantserogenez [Hormonal carcinogenesis]. Saint Petersburg: Nauka, 2000. 199 p.

17. Tilan J., Kitlinska J. Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression. J Oncol., 2010.

18. Oyfe G.R. On the relation of catecholamines in blood and urine of patients with malignant tumors of the digestive tract under physiological loading. Klinicheskaya khirurgiya, 1971, no. 5, pp. 69-72 (in Russ.).

19. Sheveleva V.S., Mel’nikov R.A., Simonov N.N. Sympathoadrenal condition in patients with malignant tumors of the gastrointestinal tract. Vopros onkologii, 1980, vol. 26, no. 8, pp. 35-41 (in Russ.).

20. Mel’nikov R.A., Popova R.T., Sheveleva V.S. Condition sympaticoadrenal system in patients with breast cancer. Vopros onkologii, 1981, vol. 27, no. 12, pp. 9-14 (in Russ.).

21. Klimenko E.M., Sheveleva V.S., Mel’nikov R.A. Catecholamine content in tumors of the gastrointestinal tract. Vopros onkologii, 1983, vol. 29, no. 2, pp. 19-25 (in Russ.).

22. Yang E.V., Sood A.K., Chen M. et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res., 2006, vol. 66, pp. 10357-10364.

23. Ben-Eliyahu S., Yirmiya R., Liebeskind J.C. et al. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain, Behavior, and Immunity, 1991, vol. 5, no. 2, pp. 193-205.

24. Yang E.V., Kim S.J., Donovan E.L. et al. Norepinephrine up-regulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun., 2009, vol. 23, no. 2, pp. 267-275.

25. Yang E.V. Role for catecholamines in tumor progression. Possible use for β-blockers in the treatment of cancer. Cancer Biol Ther., 2010, vol. 10, no. 1, pp. 30-32.

26. Moretti S., Massi D., Farini V. et al. β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab. Invest., 2013, vol. 93, no. 3, pp. 279-290.

27. Fitzgerald P.J. Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin Epidemiol., 2012, vol. 4, pp. 151-156.

28. Chakroborty D., Sarkar C., Mitra R.B. et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clinical Cancer Research., 2004, vol. 10, no. 13, pp. 4349-4356.

29. Sarkar C., Chakroborty D., Chowdhury U.R. et al. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clinical Cancer Research., 2008, vol. 14, no. 8, pp. 2502-2510.

30. Bulygina A.V. Serotonin levels in the blood of patients with lung cancer. Vopros onkologii, 1973, vol. 19, no. 8, pp. 42-44 (in Russ.).

31. Agaev B.A., Guliev B.G. Serotonin in the blood of patients with gastric cancer. Vopros onkologii, 1977, vol. 23, no. 5, pp. 50-54 (in Russ.).

32. Takeshhjo R., Hiromun I., Shojih A., Ryuheti A. Malignant melanoma producing serotonin. Cancer, 1979, vol. 43, pp. 294-298.

33. Slominski A., Semak I., Pisarchik A. et al. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett., 2002, vol. 30, 511 (1-3), pp. 102-106.

34. Dhabhar F.S., Saul A.N., Daugherty C. et al. Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma. Brain, Behavior, and Immunity, 2010, vol. 24, no. 1, pp. 127-137.

35. Entschladen F., Drell T.L., Lang K. et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol., 2004., vol. 5, no. 4, pp. 254-258.